Welcome to our dedicated page for Option Care Health news (Ticker: OPCH), a resource for investors and traders seeking the latest updates and insights on Option Care Health stock.
Option Care Health, Inc. (symbol: OPCH) is the largest independent provider of home and alternate site infusion services in the United States. With a dedicated team of over 7,500 members, including more than 4,500 clinicians, the company is at the forefront of delivering compassionate care to patients with acute and chronic conditions across all 50 states.
Formed from the merger of Option Care and BioScrip in August 2019, the company has successfully integrated its operations to create a unified national team. This merger has enabled Option Care Health to leverage its clinical leadership, extensive expertise, and national scale to reimagine the infusion care experience for patients, customers, and employees.
Option Care Health specializes in providing a variety of infusion therapies, including treatments for bleeding disorders, neurological conditions, heart failure, anti-infectives, and chronic inflammatory disorders. The company operates through home and alternate site settings, ensuring that patients receive care in a comfortable and convenient environment.
Recent achievements include strong financial performance, as highlighted in the company's third-quarter 2023 results. The CEO, John C. Rademacher, emphasized the outstanding clinical outcomes and extraordinary patient care that have contributed to these solid financial results. For the full year 2023, the company expects to generate substantial revenues and has provided updated financial guidance, reflecting its robust financial health.
The company's commitment to innovation is evident in its continuous efforts to elevate standards of care. Its clinical leadership and national scale allow Option Care Health to implement cutting-edge solutions that improve patient outcomes, reduce costs, and enhance the overall care experience.
Option Care Health's significant partnerships and collaborations further strengthen its market position. The company recently announced an increase in its share repurchase program authorization from $250 million to $500 million, demonstrating its confidence in its financial stability and future growth prospects.
For more information and the latest updates, please visit Option Care Health's Investor Relations page.
Option Care Health (NASDAQ: OPCH) collaborates with Amedisys to deliver COVID antibody infusion therapy in long-term care facilities. This initiative follows FDA Emergency Use Authorizations for treatments by Eli Lilly and Regeneron. The pilot will begin in Indianapolis and Valparaiso, Indiana, leveraging both companies' clinical resources to serve this vulnerable population effectively. Amedisys will provide on-site care coordination, while Option Care Health will manage the pharmacy operations, ensuring efficient access to critical therapies for COVID-19 positive patients.
Option Care Health, the largest independent provider of home and alternate site infusion services in the U.S., is set to present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 p.m. EST. CEO John Rademacher and CFO Mike Shapiro will lead the presentation. A replay will be available on their investor relations site. With over 5,000 employees, including 2,900 clinicians, Option Care Health is committed to improving care standards for patients with various conditions across all 50 states.
On December 10, 2020, Option Care Health (NASDAQ: OPCH) announced that an affiliate of Madison Dearborn Partners will sell 10,000,000 shares of its common stock at $15.00 per share in an underwritten public offering. The offering, expected to close on December 14, 2020, includes a 30-day option for the underwriter to purchase an additional 1,500,000 shares. This sale reduces the Selling Stockholder’s interest from 70.6% to 64.5%. Option Care Health will not receive any proceeds from this transaction.
Option Care Health (NASDAQ: OPCH) announced that an affiliate of Madison Dearborn Partners plans to sell 10,000,000 shares of its common stock in an underwritten public offering. The Selling Stockholder has granted the underwriter a 30-day option to purchase an additional 1,500,000 shares. Following this offering, the Selling Stockholder's ownership will decrease from 70.6% to 64.5%. Goldman Sachs & Co. LLC is the sole underwriter for this offering, which the Company will not benefit from financially.
Option Care Health, Inc. (Nasdaq: OPCH) reported financial results for Q3 2020, revealing a 27% increase in net revenue to $781.6 million from $615.9 million in Q3 2019. Gross profit rose to $174.2 million (22.3% of revenue), compared to $137.8 million (22.4%). The company recorded a net income of $1.7 million or $0.01 per share, a significant recovery from a $42.8 million loss last year. Adjusted EBITDA surged by 70% to $59.2 million, with operational cash flow improving to $48.3 million from a loss of $5.8 million.
Option Care Health (NASDAQ: OPCH) will release its third-quarter results for the period ending September 30, 2020, on November 3, 2020, before market opening. Following the results, a conference call is scheduled at 8:30 AM ET for management to discuss the findings. Investors can join the call via phone or a live audio webcast, with a replay available for approximately 90 days. As the largest independent provider of home and alternate site infusion services in the U.S., Option Care Health continues to elevate patient care standards.
Option Care Health (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services in the U.S., announced its participation in the Lake Street 4th Annual Best Ideas Growth Conference on September 17, 2020. Chief Financial Officer Mike Shapiro is scheduled for one-on-one meetings with investors during this virtual event. With over 5,000 teammates, including around 2,900 clinicians, Option Care Health aims to elevate care standards for patients with both acute and chronic conditions nationwide.
Option Care Health (NASDAQ: OPCH) has been chosen to join the limited distribution network for VILTEPSO™ (viltolarsen), an innovative treatment for Duchenne Muscular Dystrophy (DMD). This therapy, the first exon 53 skipping treatment approved by the FDA, shows promise for increasing dystrophin levels in young patients. Option Care Health will provide home and ambulatory infusion services for VILTEPSO across its facilities in the U.S. The company is recognized for its quality clinical care and commitment to enhancing patient outcomes.
Option Care Health, the largest independent provider of home and alternate site infusion services in the U.S., will participate in two upcoming virtual investor conferences. CFO Mike Shapiro will present at the Baird 2020 Global Healthcare Conference on September 10, 2020, at 3:10 p.m. EDT. CEO John Rademacher and CFO Mike Shapiro will present at the Morgan Stanley 18th Annual Healthcare Conference on September 14, 2020, at 9:45 a.m. EDT. Live audio webcasts will be available on their investor relations website.
Option Care Health, the largest independent provider of home and alternate site infusion services in the U.S., will present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 12, 2020, at 10:00 a.m. EST. CEO John Rademacher and CFO Mike Shapiro will lead the presentation. A live audio webcast and a replay will be available at here. With over 5,000 teammates across the nation, Option Care Health focuses on enhancing care standards for patients with various conditions.
FAQ
What is the current stock price of Option Care Health (OPCH)?
What is the market cap of Option Care Health (OPCH)?
What services does Option Care Health provide?
How many states does Option Care Health operate in?
Who are the key team members at Option Care Health?
What recent financial achievements has Option Care Health reported?
What was the impact of the merger between Option Care and BioScrip?
How does Option Care Health ensure quality care?
What is the focus of Option Care Health's innovation?
What is Option Care Health's share repurchase program?
Where can investors find more information about Option Care Health?
How can patients receive care from Option Care Health?
